Can atomoxetine be safely co‑prescribed with escitalopram (Lexapro)?

Can Atomoxetine Be Safely Co-prescribed with Lexapro?

Atomoxetine can be co-prescribed with escitalopram (Lexapro), but this combination requires careful monitoring and dose adjustment due to a clinically significant drug interaction that increases atomoxetine blood levels approximately 3-4 fold.

The Core Drug Interaction

Escitalopram is a moderate CYP2D6 inhibitor, and atomoxetine is primarily metabolized through the CYP2D6 pathway 1. When these medications are combined, escitalopram inhibits the breakdown of atomoxetine, leading to substantially elevated atomoxetine plasma concentrations—similar to levels seen in poor metabolizers 2. Specifically, the FDA label for atomoxetine notes that CYP2D6 inhibitors like fluoxetine and paroxetine (which have similar inhibitory effects to escitalopram) increase atomoxetine steady-state concentrations by 6-8 fold for AUC and 3-4 fold for peak levels 2.

Clinical Management Algorithm

If co-prescribing is necessary:

1. Start with reduced atomoxetine dosing: Begin at the lower end of the dosing range and titrate more slowly than usual, as the patient will effectively metabolize atomoxetine like a CYP2D6 poor metabolizer

2. Monitor closely for atomoxetine adverse effects, particularly:

   • Nausea, vomiting, and decreased appetite
   • Fatigue and somnolence
   • Cardiovascular effects (increased heart rate and blood pressure)
   • In children/adolescents: suicidal ideation, especially in the first few months 1

3. Consider the 7% of patients who are already poor metabolizers 1—in these individuals, adding escitalopram may not significantly change atomoxetine levels, but this cannot be predicted without genetic testing

4. Watch for serotonin syndrome: While atomoxetine is not primarily serotonergic, the combination theoretically increases risk. Monitor for agitation, confusion, tachycardia, hypertension, tremor, and hyperthermia 3

Important Caveats

The interaction is pharmacokinetic, not pharmacodynamic—meaning it affects drug levels rather than creating a direct toxic combination. However, research shows complex interactions: one animal study demonstrated that atomoxetine can actually reverse some cognitive effects of escitalopram and may reduce escitalopram-induced serotonin increases 4. The clinical significance of this in humans remains unclear.

Alternative considerations: If the patient requires both ADHD treatment and antidepressant therapy, consider:

• Using a stimulant medication instead of atomoxetine (no significant CYP2D6 interaction)
• Selecting an antidepressant that doesn't inhibit CYP2D6 (e.g., sertraline, citalopram at lower doses, venlafaxine)
• Using atomoxetine alone if it provides adequate benefit for both conditions

Bottom Line for Practice

The combination is not contraindicated but requires treating the patient as if they are a CYP2D6 poor metabolizer. Reduce atomoxetine dosing by approximately 50% when initiating with escitalopram, and titrate cautiously based on response and tolerability. The maximum atomoxetine dose should likely not exceed 1.2 mg/kg/day (rather than the usual 1.4 mg/kg/day) when combined with escitalopram 1. Close monitoring for both efficacy and adverse effects is essential, particularly during the first 8-12 weeks when both medications are reaching steady state.